The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
April 28, 2025
View Complete Issue         Table of Contents 2019 
Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia (online only)
April 28, 2025 (Issue: 1727)
The FDA has approved diazoxide choline extended-release tablets (Vykat XR – Soleno Therapeutics) for treatment of hyperphagia in patients ≥4 years old with Prader-Willi syndrome. Diazoxide choline is the first drug to be approved in the US...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Diazoxide Choline (Vykat XR) for Prader-Willi Syndrome-Associated Hyperphagia (online only)
Article code: 1727e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.